Ex-ArthroCare CEO heads lung disorder firm
This article was originally published in Clinica
Executive Summary
Michael Baker, the former president and CEO of tissue ablation technology specialist ArthroCare, has been appointed to lead Pulmonx , a Redwood City, California firm specialising in minimally-invasive treatments for pulmonary disorders. Mr. Baker was at ArthroCare for 11 years, but left in February under controversial circumstances, when an internal audit found evidence of improper business conduct by the company (see Improper practices prompt CEO to depart ArthroCare, 19/2/09). The appointment comes at a time when Pulmonx is poised for global commercialisation of its new Chartis System, a tool for assessing lung function. The product was FDA-cleared in July, and the firm is awaiting approval for CE marking.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.